Patents Assigned to MedImmune, LLC
  • Non-tumorigenic MDCK cell line for propagating viruses
    Patent number: 8119388
    Abstract: The present invention provides novel MDCK-derived adherent non-tumorigenic cell lines that can be grown in the presence or absence of serum. The cell lines of the present invention are useful for the production of vaccine material (e.g., viruses). More specifically, the cell lines of the present invention are useful for the production of influenza viruses in general and ca/ts influenza viruses in particular. The invention further provides methods and media formulations for the adaptation and cultivation of MDCK cells such that they remain non-tumorigenic. Additionally, the present invention provides methods for the production of vaccine material (e.g., influenza virus) in the novel cell lines of the invention.
    Type: Grant
    Filed: January 13, 2010
    Date of Patent: February 21, 2012
    Assignee: Medimmune, LLC
    Inventors: Richard Schwartz, John Michael Berry, Ajit Subramanian, Xiao Shi
  • STABILIZED LIQUID ANTI-RSV ANTIBODY FORMULATIONS
    Publication number: 20120039876
    Abstract: The present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS® or an antigen-binding fragment thereof even during long periods of storage. In particular, the present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof which immunospecifically binds to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides method of preventing, treating or ameliorating symptoms associated with RSV infection utilizing liquid formulations of the present invention.
    Type: Application
    Filed: July 15, 2011
    Publication date: February 16, 2012
    Applicant: MedImmune, LLC
    Inventors: Cynthia N. Oliver, Erica Shane, Benjamin S. Isaacs, Christian B. Allan, Stephen T. Chang
  • Method for producing temperature sensitive influenza A viruses
    Patent number: 8114415
    Abstract: Vectors and methods for the production of influenza viruses suitable as recombinant influenza vaccines in cell culture are provided. Bi-directional expression vectors for use in a multi-plasmid influenza virus expression system are provided. Additionally, the invention provides methods of producing influenza viruses with enhanced ability to replicate in embryonated chicken eggs and/or cells (e.g., Vero and/or MDCK) and further provides influenza viruses with enhanced replication characteristics. A method of producing a cold adapted (ca) influenza virus that replicates efficiently at, e.g., 25° C. (and immunogenic compositions comprising the same) is also provided.
    Type: Grant
    Filed: October 20, 2008
    Date of Patent: February 14, 2012
    Assignee: Medimmune, LLC
    Inventors: Erich Hoffmann, Hong Jin, Bin Lu, Gregory Duke, George Kemble, Zhongying Chen
  • INFLUENZA HEMAGGLUTININ AND NEURAMINIDASE VARIANTS
    Publication number: 20120034264
    Abstract: Polypeptides, polynucleotides, methods, compositions, and vaccines comprising (avian pandemic) influenza hemagglutinin and neuraminidase variants are provided.
    Type: Application
    Filed: June 16, 2011
    Publication date: February 9, 2012
    Applicant: MedImmune, LLC
    Inventors: Chin-Fen Yang, George Kemble
  • INFLUENZA HEMAGGLUTININ AND NEURAMINIDASE VARIANTS
    Publication number: 20120034265
    Abstract: Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided.
    Type: Application
    Filed: September 28, 2011
    Publication date: February 9, 2012
    Applicant: MEDIMMUNE, LLC
    Inventors: Chin-Fen Yang, George Kemble, Chongguang Liu
  • Methods and compositions for increasing replication capacity of an influenza virus
    Patent number: 8097459
    Abstract: In certain aspects, the present invention provides methods for increasing the replication capacity of influenza viruses in hens' eggs and/or cell culture, recombinant and/or reassortant influenza viruses with increased replication capacity, and immunogenic and vaccine compositions comprising such recombinant and/or reassortant influenza viruses. In other aspects, the invention further provides nucleic acids encoding influenza genes associated with increased replication capacity, expression vectors comprising the nucleic acids of the invention, methods for making influenza viruses with increased replication capacity, and kits useful for practice of the methods.
    Type: Grant
    Filed: September 1, 2009
    Date of Patent: January 17, 2012
    Assignee: Medimmune, LLC
    Inventors: Hong Jin, Bin Lu
  • Preservation of Bioactive Materials By Spray Drying
    Publication number: 20120009248
    Abstract: This invention provides methods and compositions to preserve bioactive materials in a matrix of powder particles. Methods provide high-pressure gas spraying and/or near supercritical spraying of formulations followed by drying in a stream of conditioned gas to form stable powder particles containing bioactive materials.
    Type: Application
    Filed: July 29, 2011
    Publication date: January 12, 2012
    Applicant: MedImmune, LLC
    Inventors: Vu Truong-Le, Binh Pham
  • ANTIBODY FORMULATIONS
    Publication number: 20120009199
    Abstract: The present invention relates to formulations comprising sucrose, and methods of making such formulations, wherein the sucrose content promotes the reduction or elimination of the reversible self-association (RSA) tendency of the antibody in the formulation. The present invention also relates to formulations comprising an anti-PDGFR-alpha antibody or antibody fragment. Such antibodies can be used in various methods of treatment. The application further relates to a method of eliminating or reducing the RSA tendency of antibodies in a formulation.
    Type: Application
    Filed: July 1, 2011
    Publication date: January 12, 2012
    Applicant: Medimmune, LLC
    Inventors: Mariana N. Dimitrova, Neil Mody
  • Multi plasmid system for the production of influenza virus
    Patent number: 8093033
    Abstract: Vectors and methods for the production of influenza viruses suitable as recombinant influenza vaccines in cell culture are provided. Bi-directional expression vectors for use in a multi-plasmid influenza virus expression system are provided. Additionally, the invention provides methods of producing influenza viruses with enhanced ability to replicate in embryonated chicken eggs and/or cells (e.g., Vero and/or MDCK) and further provides influenza viruses with enhanced replication characteristics. In addition, the present invention includes an improved method of rescue, wherein animal cells (e.g., SF Vero cells) are electroporated with plasmids and vectors of the invention.
    Type: Grant
    Filed: December 16, 2008
    Date of Patent: January 10, 2012
    Assignee: Medimmune, LLC
    Inventors: George Kemble, Gregory Duke
  • Swine influenza hemagglutinin variants
    Patent number: 8088393
    Abstract: Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided.
    Type: Grant
    Filed: June 24, 2010
    Date of Patent: January 3, 2012
    Assignee: MedImmune, LLC
    Inventor: Hong Jin
  • Recombinant parainfluenza virus expression systems and vaccines
    Patent number: 8084037
    Abstract: The present invention relates to recombinant bovine parainfluenza virus (bPIV) cDNA or RNA which may be used to express heterologous gene products in appropriate host cell systems and/or to rescue negative strand RNA recombinant viruses that express, package, and/or present the heterologous gene product. The chimeric viruses and expression products may advantageously be used in vaccine formulations including vaccines against a broad range of pathogens and antigens.
    Type: Grant
    Filed: January 27, 2010
    Date of Patent: December 27, 2011
    Assignee: MedImmune, LLC
    Inventors: Aurelia Haller, Kathleen Coelingh
  • MOLECULES WITH EXTENDED HALF-LIVES, COMPOSITIONS AND USES THEREOF
    Publication number: 20110311454
    Abstract: The present invention provides molecules, including IgGs, non-IgG immunoglobulins, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant domain or fragment for FcRn. Such proteins and molecules with increased half-lives have the advantage that smaller amounts and or less frequent dosing is required in the therapeutic, prophylactic or diagnostic use of such molecules.
    Type: Application
    Filed: July 27, 2011
    Publication date: December 22, 2011
    Applicants: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, MEDIMMUNE, LLC
    Inventors: William Dall'Acqua, Leslie S. Johnson, Elizabeth Sally Ward
  • Preservation of bioactive materials by freeze dried foam
    Patent number: 8067017
    Abstract: This invention provides methods and compositions to preserve bioactive materials in a dried foam matrix. Methods provide non-boiling foam generation and penetration of preservative agents at temperatures near the phase transition temperature of the membranes.
    Type: Grant
    Filed: October 29, 2007
    Date of Patent: November 29, 2011
    Assignee: MedImmune, LLC
    Inventor: Vu Truong-Le
  • High Affinity Antibodies Against HMGB1 and Methods of Use Thereof
    Publication number: 20110287023
    Abstract: Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise, for example, high affinity antibodies that specifically bind HMG1 and antigenic fragments thereof. The high affinity antibodies of the present invention and pharmaceutical compositions comprising the same are useful for many purposes, for example, as therapeutics against a wide range of inflammatory diseases and disorders such as sepsis, rheumatoid arthritis, peritonitis, Crohn's disease, reperfusion injury, septicemia, endotoxic shock, cystic fibrosis, endocarditis, psoriasis, psoriatic arthritis, arthritis, anaphylactic shock, organ ischemia, reperfusion injury, and allograft rejection. In addition, the high affinity antibodies of the present inventions are useful as diagnostic antibodies.
    Type: Application
    Filed: March 18, 2011
    Publication date: November 24, 2011
    Applicants: Critical Therapeutics, Inc., MedImmune, LLC
    Inventors: Herren Wu, Changshou Gao, Ling-Ling An, Peter Kiener, Su-Yau Mao, Anthony Coyle, Jane Tian, Theresa O'Keefe, Shixin Qin
  • METHODS OF PREVENTING OR TREATING T CELL MALIGNANCIES BY ADMINISTERING ANTI-CD2 ANTAGONISTS
    Publication number: 20110280868
    Abstract: The present invention encompasses the use of a CD2 antagonist, preferably MEDI-507, an analog, derivative or an antigen-binding fragment thereof as a single agent therapy for the prevention, treatment, management, or amelioration of cancer, particularly a T-cell malignancy, or one or more symptoms thereof. The present invention also encompasses the use of a CD2 antagonist, preferably MEDI-507, an analog, derivative or an antigen-binding fragment thereof in combination with other cancer therapies. The present invention provides pharmaceutical compositions comprising a CD2 antagonist, preferably MEDI-507, an analog, derivative or an antigen-binding fragment thereof in amounts effective to prevent, treat, manage, or ameliorate cancer, particularly a T-cell malignancy, or one or more symptoms thereof.
    Type: Application
    Filed: May 15, 2009
    Publication date: November 17, 2011
    Applicants: Health and Human Services, United States of America, as represented by the Sec., Medimmune, LLC
    Inventors: Christine Dingivan, Thomas Waldmann, Zhuo Zhang, Meili Zhang
  • TOXIN CONJUGATED EPH RECEPTOR ANTIBODIES
    Publication number: 20110280892
    Abstract: The present invention relates to compositions and methods for inducing cell death or stasis in cancer cells or other hyperproliferative cells using anti-EphA2 or anti-EphA4 antibodies conjugated to toxins.
    Type: Application
    Filed: December 21, 2010
    Publication date: November 17, 2011
    Applicants: MedImmune, LLC, Seattle Genetics, Inc.
    Inventors: Michael S. Kinch, Herren Wu, Christine Bachy, David Tice, Changshou Gao, Peter D. Senter
  • METHODS OF PREVENTING OR TREATING INFLAMMATORY OR AUTOIMMUNE DISORDERS BY ADMINISTERING CD2 ANTAGONISTS IN COMBINATION WITH OTHER PROPHYLACTIC OR THERAPEUTIC AGENTS
    Publication number: 20110280869
    Abstract: The present invention provides to methods of preventing, treating or ameliorating an autoimmune or inflammatory disorder or one or more symptoms thereof utilizing combinatorial therapy. In particular, the present invention provides methods of preventing, treating, or ameliorating an autoimmune or inflammatory disorder or one or more symptoms thereof comprising administering to a subject in need thereof one or more CD2 antagonists and at least one other prophylactic or therapeutic agent. The present invention also provides compositions and articles of manufacture for use in preventing, treating or ameliorating one or more symptoms associated with an autoimmune or inflammatory disorder.
    Type: Application
    Filed: January 20, 2011
    Publication date: November 17, 2011
    Applicant: MEDIMMUNE, LLC
    Inventor: Christine Dingivan
  • Influenza hemagglutinin and neuraminidase variants
    Patent number: 8048430
    Abstract: Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided.
    Type: Grant
    Filed: September 7, 2010
    Date of Patent: November 1, 2011
    Assignee: Medimmune, LLC
    Inventors: Chin-Fen Yang, George Kemble, Chongguang Liu
  • DISEASE MARKERS AND USES THEREOF
    Publication number: 20110262928
    Abstract: The present invention encompasses miRNA profiles and type-I IFN/IFN?-induced PD marker profiles in inflammatory or autoimmune disorders, such as myositis. The profiles may also be used in, for example, methods of treating patients, methods of monitoring disease progression of patients, and in diagnosing or providing a prognosis to patients having inflammatory or autoimmune disorders.
    Type: Application
    Filed: February 6, 2009
    Publication date: October 27, 2011
    Applicant: Medimmune LLC
    Inventors: Yihong Yao, Chris Moorehouse, Brandon Higgs, Bahija Jallal, Steven A. Greenberg
  • ANTIBODY FORMULATION
    Publication number: 20110256149
    Abstract: The present invention provides high concentration liquid formulations of antibodies or fragments thereof that specifically bind to a human interferon alpha polypeptide The formulation provides for an anti-13H5 anti-human interferon alpha antibody A pre-filled syringe containing the formulation is also disclosed.
    Type: Application
    Filed: October 8, 2009
    Publication date: October 20, 2011
    Applicant: MEDIMMUNE, LLC
    Inventors: Steven Bishop, Jenny S. Wolford